A5037312056- Genetic Associations and Epidemiology
- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Metabolomics and Mass Spectrometry Studies
- Health, Environment, Cognitive Aging
- Reproductive System and Pregnancy
- Bioinformatics and Genomic Networks
- Pharmacological Effects and Toxicity Studies
- Functional Brain Connectivity Studies
- Renal Diseases and Glomerulopathies
- Genetic Mapping and Diversity in Plants and Animals
- Adipose Tissue and Metabolism
- Immunotherapy and Immune Responses
- Acute Ischemic Stroke Management
- Genomics and Rare Diseases
- Amyloidosis: Diagnosis, Treatment, Outcomes
- RNA Interference and Gene Delivery
- Peripheral Neuropathies and Disorders
- Multiple Sclerosis Research Studies
- Polyomavirus and related diseases
- Cancer Genomics and Diagnostics
- Neurological Disorders and Treatments
- Cancer-related cognitive impairment studies
- Chronic Lymphocytic Leukemia Research
- Endoplasmic Reticulum Stress and Disease
Biogen (United States)
2020-2024
Rocky Mountain Multiple Sclerosis Clinic
2024
NeuroRx Research (Canada)
2024
Jersey Shore University Medical Center
2024
The Pharma Proteomics Project is a precompetitive biopharmaceutical consortium characterizing the plasma proteomic profiles of 54,219 UK Biobank participants. Here we provide detailed summary this initiative, including technical and biological validations, insights into disease signatures, prediction modelling for various demographic health indicators. We present comprehensive protein quantitative trait locus (pQTL) mapping 2,923 proteins that identifies 14,287 primary genetic associations,...
Abstract The UK Biobank Pharma Proteomics Project (UKB-PPP) is a collaboration between the (UKB) and thirteen biopharmaceutical companies characterising plasma proteomic profiles of 54,306 UKB participants. Here, we describe results from first phase UKB-PPP, including protein quantitative trait loci (pQTL) mapping 1,463 proteins that identifies 10,248 primary genetic associations, which 85% are newly discovered. We also identify independent secondary associations in 92% cis 29% trans loci,...
Abstract The circulating proteome offers insights into the biological pathways that underlie disease. Here, we test relationships between 1,468 Olink protein levels and incidence of 23 age-related diseases mortality in UK Biobank ( n = 47,600). We report 3,209 associations 963 21 incident outcomes. Next, protein-based scores (ProteinScores) are developed using penalized Cox regression. When applied to sets, six ProteinScores improve area under curve estimates for 10-year onset outcomes...
Abstract INTRODUCTION Blood tests have the potential to improve accuracy of Alzheimer's disease (AD) clinical diagnosis, which will enable greater access AD‐specific treatments. This study compared leading commercial blood for amyloid pathology and other AD‐related outcomes. METHODS Plasma samples from Disease Neuroimaging Initiative were assayed with AD C2N Diagnostics, Fujirebio ALZPath, Janssen, Roche Quanterix. Outcomes measures positron emission tomography (PET), tau PET, cortical...
This report details the approach taken to providing a dataset allowing for analyses on performance of recently developed assays amyloid beta (Aβ) peptides in plasma and extent which they improve prediction positivity.
Abstract The circulating proteome offers insights into the biological pathways that underlie disease. Here, we test relationships between 1,468 Olink protein levels and incidence of 23 age-related diseases mortality, over 16 years electronic health linkage in UK Biobank (N=47,600). We report 3,201 associations 961 21 incident outcomes, identifying proteomic indicators multiple morbidities. Next, protein-based scores (ProteinScores) are developed using penalised Cox regression. When applied...
The amyloid probability score (APS) is the model read-out of analytically validated mass spectrometry-based PrecivityAD® blood test that incorporates plasma Aβ42/40 ratio, ApoE proteotype, and age to identify likelihood brain plaques among cognitively impaired individuals being evaluated for Alzheimer's disease.This study aimed provide additional independent evidence pre-established APS algorithm, along with its cutoff values, discriminates between positive negative individuals.The...
Introduction: Blood tests have the potential to improve accuracy of Alzheimer disease (AD) clinical diagnosis, which will enable greater access AD-specific treatments. This study compared leading commercial blood for amyloid pathology and other AD-related outcomes. Methods: Plasma samples from Alzheimers Disease Neuroimaging Initiative were assayed with AD C2N Diagnostics, Fujirebio ALZPath, Janssen, Roche Quanterix. Outcomes measures positron emission tomography (PET), tau PET, cortical...
Abstract Understanding how gene-environment interactions (GEIs) influence the circulating proteome could aid in biomarker discovery and validation. The presence of GEIs can be inferred from single nucleotide polymorphisms that associate with phenotypic variability - termed variance quantitative trait loci (vQTLs). Here, vQTL association studies are performed on plasma levels 1463 proteins 52,363 UK Biobank participants. A set 677 independent vQTLs identified across 568 proteins. They include...
Exposure to natalizumab, an efficacious treatment for relapsing-remitting multiple sclerosis (RRMS), is associated with increased risk of progressive multifocal leukoencephalopathy (PML). Compared every-4-week (Q4W) dosing, extended-interval dosing natalizumab decreased PML. Clinical efficacy was maintained in the majority patients switched every-6-week (Q6W) phase 3b NOVA clinical trial. In this article, we report pharmacokinetics (PK) and pharmacodynamics (PD) Q6W vs Q4W NOVA.
<h3></h3> Interferon-alpha (IFNα)-responsive gene expression is highly upregulated in the kidneys of patients with active lupus nephritis (LN). Infiltrating plasmacytoid dendritic cells (pDCs) have been postulated to be a source intrarenal IFNα. In this study we quantified pDCs LN and correlated infiltration histologic activity chronicity. Immunohistochemistry (IHC) for BDCA-2, marker subset was used visualize pDCs. All within biopsy were counted average number glomerular tubulointerstitial...
Abstract Plasma biomarkers for Alzheimer’s disease (AD) are increasingly being used to assist in making an etiological diagnosis cognitively impaired (CI) individuals or identify unimpaired (CU) with AD pathology who may be eligible prevention trials. However, a better understanding of the timing plasma biomarker changes is needed optimize their use clinical and research settings. The aim this study was evaluate change key (Aβ42/Aβ40, p-tau217, p-tau181, GFAP NfL) from six different...
Abstract Understanding how gene-environment interactions (GEIs) influence the circulating proteome could aid in biomarker discovery and validation. The presence of GEIs can be inferred from single nucleotide polymorphisms that associate with phenotypic variability - termed variance quantitative trait loci (vQTLs). Here, vQTL association studies are performed on plasma levels 1,468 proteins 53,752 UK Biobank participants. A set 683 independent vQTLs identified across 571 proteins, all which...